Effect of Aspirin on Vascular and Nonvascular Outcomes Meta-analysis of Randomized Controlled Trials

Image via WikipediaEffect of Aspirin on Vascular and Nonvascular Outcomes

Meta-analysis of Randomized Controlled Trials

Sreenivasa Rao Kondapally Seshasai, MD, MPhil; Shanelle Wijesuriya, MA, MBBChir; Rupa Sivakumaran, MA, MBBChir; Sarah Nethercott, MA, MBBChir;Sebhat Erqou, MD, PhD; Naveed Sattar, MD, PhD; Kausik K. Ray, MD 

Arch Intern Med. Published online January 9, 2012. doi:10.1001/archinternmed.2011.628

Background  The net benefit of aspirin in prevention of CVD and nonvascular events remains unclear. Our objective was to assess the impact (and safety) of aspirin on vascular and nonvascular outcomes in primary prevention.

Data Sources  MEDLINE, Cochrane Library of Clinical Trials (up to June 2011) and unpublished trial data from investigators.

Study Selection  Nine randomized placebo-controlled trials with at least 1000 participants each, reporting on cardiovascular disease (CVD), nonvascular outcomes, or death were included.

Data Extraction  Three authors abstracted data. Study-specific odds ratios (ORs) were combined using random-effects meta-analysis. Risks vs benefits were evaluated by comparing CVD risk reductions with increases in bleeding.

Results  During a mean (SD) follow-up of 6.0 (2.1) years involving over 100 000 participants, aspirin treatment reduced total CVD events by 10% (OR, 0.90; 95% CI, 0.85-0.96; number needed to treat, 120), driven primarily by reduction in nonfatal MI (OR, 0.80; 95% CI, 0.67-0.96; number needed to treat, 162). There was no significant reduction in CVD death (OR, 0.99; 95% CI, 0.85-1.15) or cancer mortality (OR, 0.93; 95% CI, 0.84-1.03), and there was increased risk of nontrivial bleeding events (OR, 1.31; 95% CI, 1.14-1.50; number needed to harm, 73). Significant heterogeneity was observed for coronary heart disease and bleeding outcomes, which could not be accounted for by major demographic or participant characteristics.

Conclusions  Despite important reductions in nonfatal MI, aspirin prophylaxis in people without prior CVD does not lead to reductions in either cardiovascular death or cancer mortality. Because the benefits are further offset by clinically important bleeding events, routine use of aspirin for primary prevention is not warranted and treatment decisions need to be considered on a case-by-case basis.

Related articles

• Daily Aspirin Is Not for Everyone, Study Suggests (well.blogs.nytimes.com)
• Aspirin Therapy for Heart Disease, Stroke Prevention Not for Everyone (webmd.com)
• Benefits of aspirin more modest than previously believed (medicalxpress.com)
• Doctors given aspirin warning: Pills cut heart attacks by 10% but raise risk of internal bleeding by nearly a third (dailymail.co.uk)
• Routine Aspirin More Likely To Harm Than Benefit Healthy People (medicalnewstoday.com)
• Aspirin a day risk warning for healthy people (mirror.co.uk)
• Aspirin warning: Pills can cut heart attacks by 10% but raise risk of internal bleeding (dailymail.co.uk)
• Studies Examine Novel Treatment Techniques for Bleeding & Clotting Disorders (prnewswire.com)
• Daily Aspirin May Cause Internal Bleeding (news.sky.com)
• Routine aspirin 'may cause harm' (bbc.co.uk)